Agilon Health, Inc.
NYSE:AGLMedical - Care Facilities
+$2.26 today
- Market cap
- $1.52B
- Beta
- 3.04
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$22.50
Volume 0.79M
Average 0.41M
AGL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Agilon Health, Inc.NYSE: AGL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA growth accelerates
Q1 FY2026 EBITDA of $34.92M rose 421.3% year over year, ahead of the -53.6% change in trailing-twelve-month EBITDA.
Context
- EBITDA amounted to 6.2% of revenue in FY2025, up 2.6 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of $41.13M (+111.1%) for the fiscal year ending Dec 2026, a step up from the -69.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $34.92M+119.5% QoQ
- Last fiscal yearDec 2025
- -$368.86M-69.1% YoY
- LTMMar 2026
- -$340.64M-53.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +421.3% | +112.3% | -309.0 pp |
| 1 year | -69.1% | +111.1% | +180.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (368.86M) USD
- Year-over-year change
- -69.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (368.86M) | -69.1% |
| FY2024 | 2024-12-31 | (218.19M) | -30.1% |
| FY2023 | 2023-12-31 | (167.64M) | -131.5% |
| FY2022 | 2022-12-31 | (72.41M) | +80.0% |
| FY2021 | 2021-12-31 | (362.16M) | — |
EBITDA vs competitors
How AGL compares with its peers on the latest reported figures
- AGL's LTM Mar 2026 EBITDA of -$340.64M is the lowest of the 10 companies compared; the peer median is -$125.94M.
- Its year-over-year change of -53.6% is the 7th highest of 10, against a peer median of -31.0%.
- EBITDA amounts to 5.9% of revenue for AGL, versus a peer median of 27.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Feb 2026 | $17.31M | +4.6% | -7.7% | 21.5% | |
| LTM Mar 2026 | $11.6M | +101.6% | — | 4.9% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $1.72M | +21.0% | — | 27.6% |
| LTM Mar 2026 | -$66.08M | -31.0% | — | 81.4% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M | -65.1% | — | — |
| LTM Mar 2026 | -$159.48M | -49.1% | — | — | |
| LTM Mar 2026 | -$165.68M | -74.6% | — | — | |
| LTM Mar 2026 | -$193.41M | -17.1% | — | — | |
| LTM Mar 2026 | -$276.76M | -6900.5% | — | 7060.9% | |
| LTM Mar 2026 | -$340.64M | -53.6% | — | 5.9% | |
| Peer median (excluding AGL) | -$125.94M | -31.0% | -7.7% | 27.6% | |
Competitors are the stored peer set for AGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.52B | 2.39B | 4.32B | 6.06B | 5.93B |
| Cost of Revenue | 1.46B | 2.28B | 4.25B | 6.06B | 6.12B |
| Gross Profit | 65.74M | 111.36M | 69.67M | 4.84M | (188.61M) |
| Gross Margin | 4.3% | 4.7% | 1.6% | 0.1% | -3.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 427.5M | 207.79M | 285.76M | 268.91M | 238.54M |
| Operating Expenses | 437.99M | 216.74M | 301.8M | 296.97M | 232.46M |
| Depreciation & Amortization | 14.67M | 13.77M | 20.16M | 24.46M | 28.59M |
| EBITDA | (362.16M) | (72.41M) | (167.64M) | (218.19M) | (368.86M) |
| EBITDA Margin | -23.8% | -3.0% | -3.9% | -3.6% | -6.2% |
| Operating Income | (372.24M) | (105.38M) | (232.13M) | (292.13M) | (421.08M) |
| Operating Margin | -24.5% | -4.4% | -5.4% | -4.8% | -7.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 6.15M | 4.48M | 6.66M | 6.18M | 6.64M |
| Other Income / Expenses | (10.73M) | 14.71M | 37.67M | 43.3M | 16.98M |
| Income Before Tax | (382.98M) | (90.67M) | (194.46M) | (248.83M) | (404.1M) |
| Pre-Tax Margin | -25.2% | -3.8% | -4.5% | -4.1% | -6.8% |
| Income Tax Expense | 886K | 1.64M | 791K | 1.45M | 1.25M |
| Net Income | (406.49M) | (106.55M) | (262.6M) | (260.15M) | (405.35M) |
| Net Margin | -26.7% | -4.5% | -6.1% | -4.3% | -6.8% |
| EPS (Basic) | (27.25) | (6.50) | (16.00) | (15.75) | (24.50) |
| EPS (Diluted) | (27.25) | (6.50) | (16.00) | (15.75) | (24.50) |
| Weighted Avg Shares | 14.92M | 16.33M | 16.36M | 16.44M | 16.56M |
| Weighted Avg Shares (Diluted) | 14.92M | 16.33M | 16.36M | 16.44M | 16.56M |
Agilon Health, Inc.
NYSE:AGL
Intrinsic Alpha fair value
Locked
Current Price
$90.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.